Pharmacotherapy of spasticity in children with cerebral palsy

Journal of the Formosan Medical Association

Volumn 110, Issue 4, 2011, Pages 215-222

  Chung, Chia Ying ^a,b   Chen, Chia Ling ^a,b   Wong, Alice May Kuen ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Botulinum toxins; Cerebral palsy; Pharmacotherapy; Spasticity

Indexed keywords

ALCOHOL; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; PHENOL; TIZANIDINE;

ALLERGIC REACTION; BLEEDING; CEREBRAL PALSY; CHILD; DAILY LIFE ACTIVITY; DYSPHAGIA; DYSPHONIA; DYSPNEA; FATIGUE; HUMAN; INFECTION; LEG CRAMP; LIVER TOXICITY; MYALGIA; QUALITY OF LIFE; RASH; RESPIRATORY DISTRESS; REVIEW; SPASTICITY; WEAKNESS;

EID: 79957596036     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(11)60033-8     Document Type: Review

References (63)

1. Zarrinkalam R, Russo RN, Gibson CS, et al. CP or not CP? A review of diagnoses in a cerebral palsy register. Pediatr Neurol 2010;42:177-80.
2. Dodge NN. Cerebral palsy: medical aspects. Pediatr Clin N Am 2008;55:1189-207.
3. Berker AN, Yalcin MS. Cerebral palsy: orthopedic aspects and rehabilitation. Pediatr Clin N Am 2008;55:1209-25.
4. Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 2004;11:58-65.
5. Verrotti A, Greco R, Spalice A, et al. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006;34:1-6.
6. Lukban MB, Rosales RL, Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence. J Neural Transm 2009;116:319-31.
7. Damiano DL, Quinlivan J, Owen BF, et al. Spasticity versus strength in cerebral palsy: relationship among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 2001;8(Suppl 5):40-9.
8. Koman LA, Paterson B, Shilt JS. Cerebral palsy. Lancet 2004;363:1619-31.
9. Novak I, Cusick A, Lannin N. Occupational therapy home program for cerebral palsy: double-blind, randomized, controlled trial. Pediatrics 2009;124:e606-14.
10. Pennington L, Miller N, Robson S, et al. Intensive speech and language therapy for older children with cerebral palsy: a systems approach. Dev Med Child Neurol 2010;52: 337-44.
11. Merrill DR. Review of electrical stimulation in cerebral palsy and recommendations for future directions. Dev Med Child Neurol 2009;51(Suppl 4):154-65.
12. Carlson WE, Vaughan CL, Damiano DL, et al. Orthotic management of gait in spastic diplegia. Am J Phys Med Rehabil 1997;76:219-25.
13. Bobath B. The treatment of neuromuscular disorders by improving patterns of coordination. Physiotherapy 1969; 55:18-22.
14. Knox V, Evans AL. Evaluation of the functional effects of a course of Bobath therapy in children with cerebral palsy: a preliminary study. Dev Med Child Neurol 2002;44: 447-60.
15. Doman RJ, Spitz EB, Zucman E, et al. Children with severe brain injuries: neurological organization in terms of mobility. JAMA 1960;174:257-62.
16. Reddihough DS, King J, Coleman G, et al. Efficacy of programmes based on conductive education for young children with cerebral palsy. Dev Med Child Neurol 1998;40: 763-70.
17. Sterba JA. Does horseback riding therapy or therapistdirected hippotherapy rehabilitate children with cerebral palsy? Dev Med Child Neurol 2007;49:68-73.
18. Getz M, Hutzler Y, Vermeer A. Effects of aquatic interventions in children with neuromotor impairments: a systematic review of the literature. Clin Rehabil 2006;20: 927-36.
19. Barry MJ. Physical therapy interventions for patients with movement disorders due to cerebral palsy. J Child Neurol 1996;11:S51-60.
20. Stewart K. Massage for children with cerebral palsy. Nurs Times 2000;96:50-1.
21. Bar-Haim S, Harries N, Belokopytov M. Comparison of efficacy of Adeli suit and neurodevelopmental treatments in children with cerebral palsy. Dev Med Child Neurol 2006;48:325-30.
22. Charles J, Lavinder G, Gordon AM. Effects of constraintinduced therapy on hand function in children with hemiplegic cerebral palsy. Pediatr Phys Ther 2001;13:68-76.
23. Huang H, Fetters L, Hale J, et al. Bound for success: a systematic review of constraint-induced movement therapy in children with cerebral palsy supports improved arm and hand use. Phys Ther 2009;89:1126-41.
24. Ward AB. Long-term modification of spasticity. J Rehabil Med 2003;(Suppl 41):60-5.
25. Goldstein EM. Spasticity management: an overview. J Child Neurol 2001;16:16-23.
26. Chicoine MR, Park TS, Kaufman BA. Selective dorsal rhizotomy and rates of orthopedic surgery in children with spastic cerebral palsy. J Neurosurg 1997;86:34-9.
27. Carroll KL, Moore KR, Stevens PM. Orthopedic procedures after rhizotomy. J Pediatr Orthop 1998;18:69-74.
28. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Neurology 2010;74:336-43.
29. Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1981;17:107-16.
30. Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. J Child Neurol 2001;16:31-6.
31. Engle HA. The effect of diazepam (Valium) in children with cerebral palsy: a double-blind study. Dev Med Child Neurol 1996;8:661-7.
32. Hiller CJ, Mason JL. Therapeutic test of diazepam (Valium) in cerebral palsy. J S C Med Assoc 1966;62:306-9.
33. Holt KS. The use of diazepam in childhood cerebral palsy. Report of a small study including electromyographic observations. Ann Phys Med 1964;7(Suppl):16-24.
34. Carter CH. Evaluation of diazepam in skeletal muscle hypertonicity in cerebral palsy. Arch Phys Med Rehabil 1968;49:519-23.
35. Nogen AG. Medical treatment for spasticity in children with cerebral palsy. Childs Brain 1976;2:304-8.
36. Haslam RHA, Walcher R, Liteman PS, et al. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974;55:384-8.
37. Young RR, Emre M, Nance PW, et al. Current issues in spasticity management. Neurologist 1997;3:261-75.
38. Alonso RJ. Mancall EL. The clinical management of spasticity. Semin Neurol 1991;11:215-9.
39. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981;304:96-9.
40. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977;5:398-404.
41. Katz RT, Campagnolo DI. Pharmacologic management of spasticity. Phys Med Rehabil: State of the Art Reviews 1994;8:473-80.
42. Terrence CF, Fromm GH. Complication of baclofen withdrawal. Arch Neurol 1981;38:588-9.
43. Nance PW, Young RR. Antispasticity medications. Phys Med Rehabil Clin North Am 1999;10:337-55.
44. Young RR. Spasticity: a review. Neurology 1994;44:12-20.
45. Spira R. Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol 1971;13:164-73.
46. Yadav SL, Singh U, Dureja GP, et al. Phenol block in the management of spastic cerebral palsy. Indian J Pediatr 1994;61:249-55.
47. Carpenter EB, Seitz DG. Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol 1980;22:497-501.
48. Tardieu G, Tardieu C, Hariga J. Selective partial denervation by alcohol injections and their results in spasticity. Reconstr Surg Traumatol 1972;13:18-36.
49. Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007;120:49-58.
50. Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79.
51. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001; 8(Suppl 5):1-20.
52. Albavera-Hernandez C, Rodriguez JM, Idrovo AJ. Safety of botulinim toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 2009;23:394-407.
53. Heinen F, Desloovere K, Schroeder AS, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010; 14:45-66.
54. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997;6(Suppl):S146-98.
55. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type A neuromuscular blockade in the treatment of equines foot deformity in cerebral palsy. A multicenter, open-label clinical trial. Pediatrics 2001;108:1062-71.
56. On AY, Kirazli Y, Kismali B. Mechanisms of action of phenol block and botulinus toxin type A in relieving spasticity: electrophysiologic investigation and follow-up. Am J Phys Med Rehabil 1999;78:344-9.
57. Gracies JM, Elovic E, McGuire J, et al. Traditional pharmacological treatments for spasticity part I: local treatments. Muscle Nerve 1997;6(Suppl):S61-91.
58. Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol 2003;18:S50-66.
59. Coffey RJ, Cahell D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993;78:226-32.
60. Gilmartin R, Bruce D, Storrs BB, et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol 2000;15:71-7.
61. Gracies JM, Nance P, Elovic E, et al. Traditional pharmacological treatments for spasticity part II: general and regional treatments. Muscle Nerve 1997;20(Suppl 6):S92-120.
62. Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991;265:1418-22.
63. Borowski A, Littleton AG, Borkhuu B, et al. Complications of intrathecal baclofen pump therapy in pediatric patients. J Pediatr Orthop 2010;30:76-81.